Work

Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial

Year: 2012

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2012-202221

Authors: René Westhovens, Filip De Keyser, Dmytro Rekalov, Evgeny L Nasonov, Johan Beetens, Annegret Van der Aa, Piet Wigerinck, Florence Namour, Frédéric Vanhoutte, Patrick Durez

Institutions: Universitair Ziekenhuis Leuven, KU Leuven, Ghent University Hospital, Galapagos (Belgium), Galapagos (France), UCLouvain

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2107355697

FWCI: 1.469

Cites: 10

Cited by: 23

Related to: 10